T1	PROC 77 114	determinar la eficacia y la seguridad
#1	AnnotatorNotes T1	C0511730; Identify product efficacy and safety issues; Health Care Activity
T2	CHEM 118 128	durvalumab
#2	AnnotatorNotes T2	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	CHEM 148 159	gemcitabina
#3	AnnotatorNotes T3	C0045093; gemcitabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T4	CHEM 162 172	cisplatino
#4	AnnotatorNotes T4	C0008838; cisplatin; Inorganic Chemical · Pharmacologic Substance
T5	PROC 178 202	tratamiento neoadyuvante
#5	AnnotatorNotes T5	C0600558; Neoadjuvant Therapy; Therapeutic or Preventive Procedure
T6	CHEM 214 224	durvalumab
#6	AnnotatorNotes T6	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T7	PROC 228 239	monoterapia
#7	AnnotatorNotes T7	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T8	PROC 245 266	tratamiento adyuvante
#8	AnnotatorNotes T8	C0677850; Adjuvant therapy; Therapeutic or Preventive Procedure
T9	DISO 284 317	cáncer de vejiga músculo invasivo
T10	ANAT 301 308	músculo
#9	AnnotatorNotes T10	C0026845; Muscle Tissue; Tissue | C4083049; Muscle (organ); Body Part, Organ, or Organ Component
T11	PROC 340 409	Ensayo fase III, aleatorizado, abierto, multicéntrico e internacional
T12	CHEM 456 466	durvalumab
#10	AnnotatorNotes T12	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T13	CHEM 486 497	gemcitabina
#11	AnnotatorNotes T13	C0045093; gemcitabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T14	CHEM 500 510	cisplatino
#12	AnnotatorNotes T14	C0008838; cisplatin; Inorganic Chemical · Pharmacologic Substance
T15	PROC 516 540	tratamiento neoadyuvante
#13	AnnotatorNotes T15	C0600558; Neoadjuvant Therapy; Therapeutic or Preventive Procedure
T16	CHEM 552 562	durvalumab
#14	AnnotatorNotes T16	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T17	PROC 566 577	monoterapia
#15	AnnotatorNotes T17	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T18	PROC 583 604	tratamiento adyuvante
#16	AnnotatorNotes T18	C0677850; Adjuvant therapy; Therapeutic or Preventive Procedure
T19	DISO 622 655	cáncer de vejiga músculo invasivo
T20	ANAT 639 646	músculo
#17	AnnotatorNotes T20	C0026845; Muscle Tissue; Tissue | C4083049; Muscle (organ); Body Part, Organ, or Organ Component
T21	DISO 689 722	Cáncer de Vejiga Músculo Invasivo
T22	ANAT 706 713	Músculo
#18	AnnotatorNotes T22	C0026845; Muscle Tissue; Tissue | C4083049; Muscle (organ); Body Part, Organ, or Organ Component
T23	DISO 757 794	afectación de los ganglios linfáticos
T24	ANAT 775 794	ganglios linfáticos
#19	AnnotatorNotes T24	C0024204; lymph nodes; Body Part, Organ, or Organ Component | C1269047; Entire lymph node; Body Part, Organ, or Organ Component
T25	DISO 835 880	carcinoma de vejiga de células transicionales
T26	DISO 882 885	CCT
#20	AnnotatorNotes T26	C0007138; Carcinoma, Transitional Cell; Neoplastic Process
T27	DISO 973 1006	cáncer de vejiga músculo invasivo
T28	ANAT 990 997	músculo
#21	AnnotatorNotes T28	C0026845; Muscle Tissue; Tissue | C4083049; Muscle (organ); Body Part, Organ, or Organ Component
T29	ANAT 1070 1092	células transicionales
#22	AnnotatorNotes T29	C0225340; Transitional Epithelial Cells; Cell
T30	PROC 1148 1167	cistectomía radical
#23	AnnotatorNotes T30	C0194401; Complete cystectomy; Therapeutic or Preventive Procedure
T31	PROC 1188 1202	aleatorización
#24	AnnotatorNotes T31	C0034656; Randomization; Research Activity
T32	PROC 1241 1254	quimioterapia
#25	AnnotatorNotes T32	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T33	PROC 1257 1280	inmunoterapia sistémica
T34	PROC 1296 1307	tratamiento
#26	AnnotatorNotes T34	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T35	DISO 1433 1438	tumor
#27	AnnotatorNotes T35	C0006826; Malignant Neoplasms; Neoplastic Process | C0027651; Neoplasms; Neoplastic Process | C0577559; Mass of body structure; Finding
T36	ANAT 1421 1438	muestra del tumor
T37	PROC 1537 1551	aleatorización
#28	AnnotatorNotes T37	C0034656; Randomization; Research Activity
T38	ANAT 1611 1630	ganglios linfáticos
#29	AnnotatorNotes T38	C0024204; lymph nodes; Body Part, Organ, or Organ Component | C1269047; Entire lymph node; Body Part, Organ, or Organ Component
T39	DISO 1633 1655	enfermedad metastásica
#30	AnnotatorNotes T39	C2939420; Metastatic Neoplasm; Neoplastic Process
T40	CHEM 1725 1737	medicamentos
#31	AnnotatorNotes T40	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T41	CHEM 1760 1770	medicación
#32	AnnotatorNotes T41	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T42	PROC 1774 1789	inmunosupresión
#33	AnnotatorNotes T42	C0021079; Therapeutic immunosuppression; Therapeutic or Preventive Procedure
T43	DISO 1822 1862	Alteraciones autoinmunes o inflamatorias
T44	DISO 1798 1820	condición concomitante
T45	PROC 415 452	determinar la eficacia y la seguridad
#34	AnnotatorNotes T45	C0511730; Identify product efficacy and safety issues; Health Care Activity
T46	ANAT 294 300	vejiga
#35	AnnotatorNotes T46	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T47	ANAT 632 638	vejiga
#36	AnnotatorNotes T47	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T48	ANAT 699 705	Vejiga
#37	AnnotatorNotes T48	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T49	ANAT 848 854	vejiga
#38	AnnotatorNotes T49	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T50	ANAT 858 880	células transicionales
#39	AnnotatorNotes T50	C0225340; Transitional Epithelial Cells; Cell
T51	ANAT 983 989	vejiga
#40	AnnotatorNotes T51	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T52	DISO 1592 1630	implicación de los ganglios linfáticos
T53	Date 13 17	2018
T54	LIVB 270 279	pacientes
#41	AnnotatorNotes T54	C0030705; Patients; Patient or Disabled Group
T55	LIVB 608 617	pacientes
#42	AnnotatorNotes T55	C0030705; Patients; Patient or Disabled Group
T56	Neg_cue 753 756	sin
T57	LIVB 821 830	Pacientes
#43	AnnotatorNotes T57	C0030705; Patients; Patient or Disabled Group
T58	LIVB 960 968	Paciente
#44	AnnotatorNotes T58	C0030705; Patients; Patient or Disabled Group
T59	LIVB 1099 1108	pacientes
#45	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T60	LIVB 1209 1218	pacientes
#46	AnnotatorNotes T60	C0030705; Patients; Patient or Disabled Group
T61	Neg_cue 1223 1225	no
T62	Duration 1511 1530	al menos 12 semanas
T64	PROC 1056 1066	histología
#47	AnnotatorNotes T64	C0344441; Histology Procedure; Laboratory Procedure
T63	PROC 899 915	histológicamente
#48	AnnotatorNotes T63	C0344441; Histology Procedure; Laboratory Procedure
T65	PROC 918 933	citológicamente
#49	AnnotatorNotes T65	C1305671; Cytology procedure; Laboratory Procedure
T66	PROC 1387 1400	reclutamiento
#50	AnnotatorNotes T66	C0242800; Patient Recruitment; Research Activity
A1	Assertion T23 Negated
A2	Assertion T32 Negated
A3	Assertion T33 Negated
A4	Status T32 History_of
A5	Status T33 History_of
A6	Assertion T40 Contraindicated
A7	Status T43 History_of
#51	AnnotatorNotes T25	C0007138; Carcinoma, Transitional Cell; Neoplastic Process
#52	AnnotatorNotes T36	C0475358; Tumor tissue sample; Tissue
#53	AnnotatorNotes T23	C0806692; Lymph Node Involvement; Finding
#54	AnnotatorNotes T52	C0806692; Lymph Node Involvement; Finding
#55	AnnotatorNotes T33	C5400982; Systemic Inmunotherapy; Therapeutic or Preventive Procedure 
#56	AnnotatorNotes T44	C0243087; concomitant disease; Pathologic Function
R1	Negation Arg1:T56 Arg2:T23	
R2	Negation Arg1:T61 Arg2:T32	
R3	Negation Arg1:T61 Arg2:T33	
R4	Combined_with Arg1:T2 Arg2:T3	
R5	Combined_with Arg1:T3 Arg2:T4	
R6	Used_for Arg1:T2 Arg2:T5	
R7	Before Arg1:T2 Arg2:T6	
R8	Used_for Arg1:T6 Arg2:T7	
R9	Used_for Arg1:T6 Arg2:T8	
R10	Experiences Arg1:T54 Arg2:T2	
R11	Experiences Arg1:T54 Arg2:T6	
R12	Experiences Arg1:T54 Arg2:T9	
R13	Location_of Arg1:T46 Arg2:T9	
T67	Observation 301 317	músculo invasivo
#57	AnnotatorNotes T67	C4725840; Muscle Invasion; Finding
R15	Location_of Arg1:T10 Arg2:T67	
T68	Observation 706 722	Músculo Invasivo
#58	AnnotatorNotes T68	C4725840; Muscle Invasion; Finding
R14	Location_of Arg1:T22 Arg2:T68	
R16	Location_of Arg1:T48 Arg2:T21	
T69	Observation 639 655	músculo invasivo
#59	AnnotatorNotes T69	C4725840; Muscle Invasion; Finding
R17	Location_of Arg1:T20 Arg2:T69	
R18	Location_of Arg1:T47 Arg2:T19	
R19	Location_of Arg1:T51 Arg2:T27	
T70	Observation 990 1006	músculo invasivo
#60	AnnotatorNotes T70	C4725840; Muscle Invasion; Finding
R20	Location_of Arg1:T28 Arg2:T70	
#61	AnnotatorNotes T21	C4725841; Muscle Invasive Bladder Carcinoma; Neoplastic Process
#62	AnnotatorNotes T9	C4725841; Muscle Invasive Bladder Carcinoma; Neoplastic Process
#63	AnnotatorNotes T19	C4725841; Muscle Invasive Bladder Carcinoma; Neoplastic Process
#64	AnnotatorNotes T27	C4725841; Muscle Invasive Bladder Carcinoma; Neoplastic Process
T71	Quantifier_or_Qualifier 735 752	estadío II y IIIA
R21	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T71	
R22	Location_of Arg1:T24 Arg2:T23	
T72	Observation 724 726	T2
#65	AnnotatorNotes T72	C0475373; Tumor stage T2; Finding
T73	Observation 727 730	T4a
#66	AnnotatorNotes T73	C0475395; Tumor stage T4a; Finding
R23	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T72	
R24	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T73	
R25	Overlap Arg1:T21 Arg2:T23	
R26	Combined_with Arg1:T12 Arg2:T13	
R27	Combined_with Arg1:T13 Arg2:T14	
R28	Used_for Arg1:T12 Arg2:T15	
R29	Before Arg1:T12 Arg2:T16	
R30	Used_for Arg1:T16 Arg2:T17	
R31	Used_for Arg1:T16 Arg2:T18	
R32	Experiences Arg1:T55 Arg2:T12	
R33	Experiences Arg1:T55 Arg2:T16	
R34	Experiences Arg1:T55 Arg2:T19	
R35	Experiences Arg1:T55 Arg2:T69	
R37	Experiences Arg1:T57 Arg2:T25	
R38	Location_of Arg1:T49 Arg2:T25	
R39	Location_of Arg1:T50 Arg2:T25	
R40	Location_of Arg1:T50 Arg2:T26	
R41	Location_of Arg1:T49 Arg2:T26	
R46	Experiences Arg1:T58 Arg2:T27	
R47	Experiences Arg1:T58 Arg2:T70	
T74	Quantifier_or_Qualifier 1007 1016	resecable
#67	AnnotatorNotes T74	C1514888; Resectable; Qualitative Concept
R48	Has_Quantifier_or_Qualifier Arg1:T27 Arg2:T74	
T75	Observation 1037 1051	T2N0M0-T4aN0M0
R49	Has_Quantifier_or_Qualifier Arg1:T27 Arg2:T75	
R51	Location_of Arg1:T29 Arg2:T27	
R52	Experiences Arg1:T58 Arg2:T64	
R53	Experiences Arg1:T59 Arg2:T30	
T76	Quantifier_or_Qualifier 1121 1131	programado
#68	AnnotatorNotes T76	C0205539; Scheduled - procedure status; Qualitative Concept
R54	Has_Quantifier_or_Qualifier Arg1:T30 Arg2:T76	
R56	Experiences Arg1:T60 Arg2:T32	
R57	Experiences Arg1:T60 Arg2:T33	
R58	Before Arg1:T32 Arg2:T34	
R59	Before Arg1:T33 Arg2:T34	
T77	DISO 1312 1316	CVIM
#69	AnnotatorNotes T77	C4725841; Muscle Invasive Bladder Carcinoma; Neoplastic Process
R60	Experiences Arg1:T60 Arg2:T77	
T78	CONC 1330 1334	ECOG
#70	AnnotatorNotes T78	C1520224; ECOG performance status; Intellectual Product
T79	CONC 1336 1370	Eastern Cooperative Oncology Group
#71	AnnotatorNotes T79	C1520224; ECOG performance status; Intellectual Product
R61	Overlap Arg1:T79 Arg2:T66	
R62	Overlap Arg1:T78 Arg2:T66	
T80	Result_or_Value 1375 1380	0 o 1
R63	Has_Result_or_Value Arg1:T78 Arg2:T80	
R64	Has_Result_or_Value Arg1:T79 Arg2:T80	
T81	Observation 1451 1472	entrada en el estudio
#72	AnnotatorNotes T81	C0422726; Patient entered into trial; Finding 
R65	Before Arg1:T36 Arg2:T81	
T82	CONC 1490 1507	esperanza de vida
#73	AnnotatorNotes T82	C0023671; Life Expectancy; Group Attribute
R66	Has_Duration_or_Interval Arg1:T82 Arg2:T62	
R67	Overlap Arg1:T82 Arg2:T37	
R68	Location_of Arg1:T38 Arg2:T52	
T83	PROC 1676 1685	selección
#74	AnnotatorNotes T83	C0242802; Patient Selection; Research Activity
R69	Overlap Arg1:T52 Arg2:T83	
R70	Overlap Arg1:T39 Arg2:T83	
R71	Used_for Arg1:T41 Arg2:T42	
T84	Quantifier_or_Qualifier 1863 1870	activas
#75	AnnotatorNotes T84	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R72	Has_Quantifier_or_Qualifier Arg1:T43 Arg2:T84	
#76	AnnotatorNotes T43	C0004364; Autoimmune Diseases; Disease or Syndrome | C0021368; Inflammation; Pathologic Function
R36	Overlap Arg1:T30 Arg2:T31	
R42	Experiences Arg1:T60 Arg2:T34	
R43	Experiences Arg1:T57 Arg2:T26	
#77	AnnotatorNotes T75	C0475373; Tumor stage T2; Finding + C0475374; Tumor stage T3; Finding + C0475395; malignant neoplasm stage T4a; Finding + C0441959; Node stage N0; Finding + C0445034; M0 Stage Finding; Finding
A8	Experiencer T54 Patient
A9	Experiencer T55 Patient
A10	Experiencer T57 Patient
A11	Experiencer T58 Patient
A12	Experiencer T59 Patient
A13	Status T30 Future
A14	Experiencer T60 Patient
